August 11, 2020
Webinar
Strafford Publications
As part of Strafford Publications' webinar series, Finnegan partners Mark Feldstein, Tom Irving, Jill MacAlpine, Barbara Rudolph, and David Weingarten will provide guidance to patent counsel on the essentials of patent exclusivity that are in critical need of independent checking. The panel will discuss crucial health checks on U.S. patent exclusivity for small molecules in Phase II efficacy trials and proceedings through large-scale randomized Phase III clinical trials, submission of the NDA, and subsequent approval and marketing. For more information, or to register, please see Strafford’s website.
Hatch-Waxman Act, drugs, enforcement, ex parte reexamination, inventorship, new drug application (NDA), Orange Book, patent exclusivity, Patent Trial and Appeal Board (PTAB), supplemental examination, United States Court of Appeals for the Federal Circuit (CAFC)
Lecture
Patent Protection for Software-Related Inventions in Europe and the USA Training Course
June 5, 2024
Hybrid
Workshop
Life Sciences Workshop: Updates and Key Trends in Pharmaceutical and Biotechnology IP Law
May 2, 2024
Cambridge
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.